Spring allergy seasons are growing longer and more intense for many people. Noah Greenspan, PT, DPT, a board-certified clinical specialist in cardiovascular and pulmonary physical…
On his 16th birthday in 2020, Dylan Kurtz learned that his father, Jonathan, would begin chemotherapy for stage 3 colon cancer.
New research shows that elevated blood pressure in the 30s is linked to higher risks of cardiovascular and kidney disease later in life, highlighting the importance of earlier…
New research suggests that sustained elevated blood pressure in young adulthood is linked to greater risk of both heart and kidney disease later in life, underscoring the need to…
In 2010, while in her 20s and finishing graduate school, Jamie Harris began having digestive trouble after a trip to London.
On March 31, 2026 the American Heart Association published updated dietary guidance in Circulation aimed at improving cardiovascular health and reducing heart disease risk.
The NHS will start offering the GLP-1 drug semaglutide (Wegovy) to eligible patients in England within months, as draft guidance from NICE recommends its use from this summer.
A recent clinical trial published in JACC found that baduanjin, a traditional mind‑body exercise related to qigong, lowered systolic blood pressure in people with hypertension.
On March 19 the FDA approved a higher-dose version of the weight-loss drug Wegovy. Branded as Wegovy HD, the new formulation delivers 7.2 mg of semaglutide by weekly injection, up from…
A large Swedish registry study suggests that GLP-1 receptor agonists — notably semaglutide (marketed as Ozempic and Wegovy) and liraglutide — are associated with a lower risk of…
Stopping GLP-1 medications such as semaglutide (Ozempic, Wegovy) can rapidly erase the cardiovascular gains achieved while using them.
On November 26, 2025, 62-year-old Tommy Bell, a patient transport supervisor at AdventHealth DeLand who had worked at the hospital for more than a decade, felt persistent pressure in…